The name Gossamer Bio depicts the symbolism behind the gossamer thread, the invisible and fragile connection that binds all relationships in life. In our context, this is intended to highlight the importance of our relationships with our employees, shareholders, providers, partners and patients in a healthcare system. We take these relationships seriously and aim to continuously strengthen these connections. Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.
Co-Founder, Chairman, and Chief Executive Officer
Richard Aranda, M.D.
Chief Medical Officer
General Counsel and Secretary
Laura Carter, Ph.D.
Chief Scientific Officer
Senior Vice President, Biometrics
Chief Operating Officer & Chief Financial Officer
Lisa Nolan, Ph.D.
Managing Director and President, Gossamer Bio Ireland
Senior Vice President, Commercial New Product Planning
Executive Vice President, Regulatory Affairs
Colin Rowlings, Ph.D.
Senior Vice President, CMC
Executive Vice President, Technical Operations & Administration
Senior Vice President, Human Resources